Clinical Trial Update: TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278 [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the safety, tolerability, and pharmacokinetics of a single-dose or multi-dose IM long-acting formulation of TMC278 (rilpivirine) in HI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC278 long-acting injectable (rilpivirine) (rilpivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 1 | Status: COMPLETED